<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432315</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_AT1_203</org_study_id>
    <nct_id>NCT00432315</nct_id>
  </id_info>
  <brief_title>Docetaxel in Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      • To assess the response rate to induction therapy with docetaxel/CDDP.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To assess&#xD;
&#xD;
        -  Resectability after induction therapy&#xD;
&#xD;
        -  Time to progression&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Safety profile&#xD;
&#xD;
        -  Quality of Life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response rate to induction therapy with docetaxel in combination with CDDP</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability after induction therapy</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resectable NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unresectable NSCSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + CDDP</intervention_name>
    <description>3 cycles chemotherapy : docetaxel + CDDP&#xD;
Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)&#xD;
3 cycles adjuvant chemotherapy docetaxel</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel + CDDP</intervention_name>
    <description>3 cycles chemotherapy: docetaxel + CDDP&#xD;
Radiochemotherapy&#xD;
3 cycles adjuvant chemotherapy docetaxel</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histology and staging of the disease&#xD;
&#xD;
               -  Histologically or cytologically confirmed NSCLC; histology may include: large&#xD;
                  cell, squamous cell or adenocarcinoma but no SCLC&#xD;
&#xD;
               -  Resectable or unresectable NSCLC stage II (T1-2 N1, T3 N0) or stage IIIa (T1-2 N2&#xD;
                  or T3 N1-2) or stage IIIb (T1-3 N3 or T4 N0-3)&#xD;
&#xD;
               -  Measurable disease (bidimensionally or unidimensionally according to WHO&#xD;
                  criteria)&#xD;
&#xD;
          2. General conditions&#xD;
&#xD;
               -  Karnofsky Status &gt; 70, if age &gt; 70 years → PS &gt; 70&#xD;
&#xD;
               -  Adequate hematological function (Hb &gt; 10 g/dl, ANC &gt; 2.0 x 109/L, platelets &gt; 100&#xD;
                  x 109/L)&#xD;
&#xD;
               -  Adequate renal and hepatic functions: total bilirubin &lt; 1 x upper normal limit&#xD;
                  (UNL), serum creatinine &lt; 1 x UNL, in case of limit value the creatinine&#xD;
                  clearance should be &gt; 60 ml/min, ASAT and ALAT &lt; 2.5 x UNL, alkaline phosphatase&#xD;
                  &lt; 5 x UNL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis&#xD;
&#xD;
               -  Evidence of brain metastases or other distant metastasis equivalent to stage IV&#xD;
                  disease&#xD;
&#xD;
               -  History of prior malignancies, except for curatively treated non-melanoma skin&#xD;
                  cancer or in situ carcinoma of the cervix or other curatively treated cancer with&#xD;
                  no evidence of disease for at least five years&#xD;
&#xD;
               -  Other serious concomitant illness or medical condition:&#xD;
&#xD;
                    -  Congestive heart failure or angina pectoris, except if medically controlled,&#xD;
                       history of myocardial infarction within 1 year from study entry,&#xD;
                       uncontrolled hypertension or arrhythmia&#xD;
&#xD;
                    -  History of significant neurologic or psychiatric disorders, including&#xD;
                       dementia or seizure&#xD;
&#xD;
                    -  Active infection requiring i.v. Antibiotics&#xD;
&#xD;
                    -  Active ulcer, unstable diabetes mellitus or other contraindications to&#xD;
                       corticotherapy&#xD;
&#xD;
               -  Hepatic function abnormality: ASAT and/or ALAT &gt; 1.5 x UNL associated with&#xD;
                  alkaline phosphatase &gt; 2.5 x UNL&#xD;
&#xD;
               -  Current peripheral neuropathy WHO grade &gt; 2&#xD;
&#xD;
          2. Prior or concurrent therapy&#xD;
&#xD;
               -  Prior chemotherapy or immunotherapy for NSCLC, including neoadjuvant or adjuvant&#xD;
                  treatment&#xD;
&#xD;
               -  Prior surgery or radiotherapy for NSCLC&#xD;
&#xD;
               -  Concurrent treatment with other experimental drugs, unapproved medical procedures&#xD;
                  or other anticancer therapy&#xD;
&#xD;
          3. General conditions&#xD;
&#xD;
               -  Pregnant or lactating patients&#xD;
&#xD;
               -  Patients (M/F) with reproductive potential not implementing adequate&#xD;
                  contraceptive measurements&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Edlmayer, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

